Skip to main content

Simard John's Form 4 filing

XBiotech Inc. (XBIT) · filed Sep 22, 2021

Accession no.
0001209191-21-057295
Filed
Sep 22, 2021
Trade date
Sep 20-22, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $757.6K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Simard JohnCIK 0001639078Director, Officer (Chief Executive Officer), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 20, 2021Common StockSSaleDisposed−13,471$15.06F1−$202,873.264,159,695Direct
Sep 21, 2021Common StockSSaleDisposed−16,860$15.24F1−$256,946.44,142,835Direct
Sep 22, 2021Common StockSSaleDisposed−19,669$15.14F1−$297,788.664,123,166Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Referenced by the price of 3 transactions in Table I.

Remarks

John Simard, CEO Chairman of XBiotech, Inc., adopted a stock trading plan. He sold total of 500,000 common stock on the open market as part of this 10B5-1 trading plan.

Read the full filing on SEC EDGAR (opens in a new tab)